Anti–tumor necrosis factor agents are now considered to be a vital component of the treatment algorithm for pediatric inflammatory bowel disease.
Despite the clear benefit of these agents and the realignment of treatment goals to achieve early mucosal healing, the decision to initiate therapy is often delayed due to uncertainties regarding risks and benefits.
Dr Marla Dubinsky and colleagues from California, USA summarized the currently available data regarding anti–tumor necrosis factor agents in pediatric inflammatory bowel disease.
|The team address the barriers physicians face when communicating these data|
|Inflammatory Bowel Diseases|
The research team reviewed their expected efficacy in both Crohn’s disease and ulcerative colitis and the likelihood of side effects associated with these agents.
In addition, the team address the barriers physicians face when communicating these data, and help to identify how pediatric patients and their parents can be more involved in a shared decision-making process.
Dr Dubinsky's team concludes, "Through the creation of a new decision aid (Option Grid), we hope to allow for a more clear line of communication at the bedside when helping patients and parents make these difficult treatment decisions."